CN101410389A - 有机化合物 - Google Patents

有机化合物 Download PDF

Info

Publication number
CN101410389A
CN101410389A CNA2007800110014A CN200780011001A CN101410389A CN 101410389 A CN101410389 A CN 101410389A CN A2007800110014 A CNA2007800110014 A CN A2007800110014A CN 200780011001 A CN200780011001 A CN 200780011001A CN 101410389 A CN101410389 A CN 101410389A
Authority
CN
China
Prior art keywords
alkyl
hydrogen
alkylamino
aryl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800110014A
Other languages
English (en)
Chinese (zh)
Inventor
C·亚当斯
J·巴比隆
G·M·克桑德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101410389A publication Critical patent/CN101410389A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CNA2007800110014A 2006-03-29 2007-03-27 有机化合物 Pending CN101410389A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78710406P 2006-03-29 2006-03-29
US60/787,104 2006-03-29

Publications (1)

Publication Number Publication Date
CN101410389A true CN101410389A (zh) 2009-04-15

Family

ID=38477291

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800110014A Pending CN101410389A (zh) 2006-03-29 2007-03-27 有机化合物

Country Status (12)

Country Link
US (1) US8153674B2 (https=)
EP (2) EP2001866A2 (https=)
JP (1) JP5197569B2 (https=)
KR (1) KR20080114769A (https=)
CN (1) CN101410389A (https=)
AU (1) AU2007234968A1 (https=)
BR (1) BRPI0709678A2 (https=)
CA (1) CA2644391A1 (https=)
ES (1) ES2442347T3 (https=)
MX (1) MX2008012402A (https=)
RU (1) RU2008142600A (https=)
WO (1) WO2007117982A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958478A (zh) * 2011-11-30 2014-07-30 霍夫曼-拉罗奇有限公司 新双环二氢异喹啉-1-酮衍生物
CN106488921A (zh) * 2014-07-24 2017-03-08 勃林格殷格翰国际有限公司 醛固酮合成酶抑制剂
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
WO2024109885A1 (zh) * 2022-11-23 2024-05-30 上海翰森生物医药科技有限公司 吡啶多环类化合物抑制剂、及其制备方法和应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20090090395A (ko) * 2006-12-18 2009-08-25 노파르티스 아게 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도
EA200900811A1 (ru) * 2006-12-18 2009-12-30 Новартис Аг Имидазолы в качестве ингибиторов альдостеронсинтазы
EP2095819A1 (en) 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
AR088989A1 (es) * 2011-11-30 2014-07-23 Hoffmann La Roche Derivados biciclicos de dihidroisoquinolin-1-ona
EP2639212B1 (en) 2012-03-13 2016-03-09 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Enantioselective organic anhydride reactions
WO2016123275A1 (en) * 2015-01-30 2016-08-04 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
WO2018165649A1 (en) 2017-03-10 2018-09-13 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
EP3962903A1 (en) 2019-05-01 2022-03-09 Boehringer Ingelheim International GmbH (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
TW202339719A (zh) 2021-12-14 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療慢性腎臟病之醛固酮合成酶抑制劑

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904300A (en) * 1987-08-26 1990-02-27 Ciba-Geigy Corp. Imidazole derivatives
DE102004035322A1 (de) * 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958478A (zh) * 2011-11-30 2014-07-30 霍夫曼-拉罗奇有限公司 新双环二氢异喹啉-1-酮衍生物
CN106488921A (zh) * 2014-07-24 2017-03-08 勃林格殷格翰国际有限公司 醛固酮合成酶抑制剂
TWI600658B (zh) * 2014-07-24 2017-10-01 百靈佳殷格翰國際股份有限公司 醛固酮合成酶抑制劑
CN106488921B (zh) * 2014-07-24 2019-03-15 勃林格殷格翰国际有限公司 醛固酮合成酶抑制剂
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
WO2024109885A1 (zh) * 2022-11-23 2024-05-30 上海翰森生物医药科技有限公司 吡啶多环类化合物抑制剂、及其制备方法和应用

Also Published As

Publication number Publication date
WO2007117982A2 (en) 2007-10-18
EP2301931B1 (en) 2013-10-16
CA2644391A1 (en) 2007-10-18
US8153674B2 (en) 2012-04-10
ES2442347T3 (es) 2014-02-11
EP2001866A2 (en) 2008-12-17
RU2008142600A (ru) 2010-05-10
AU2007234968A1 (en) 2007-10-18
US20090182007A1 (en) 2009-07-16
JP2009531457A (ja) 2009-09-03
JP5197569B2 (ja) 2013-05-15
WO2007117982A3 (en) 2007-12-13
MX2008012402A (es) 2008-10-09
BRPI0709678A2 (pt) 2011-07-19
KR20080114769A (ko) 2008-12-31
EP2301931A1 (en) 2011-03-30

Similar Documents

Publication Publication Date Title
CN101410389A (zh) 有机化合物
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
JP6856543B2 (ja) ブロモドメイン阻害剤
JP4592077B2 (ja) 嘔吐、抑鬱、不安および咳の処置のためのニューロキニン−１（ｎｋ−１）アンタゴニストとしての１−アミド−４−フェニル−４−ベンジルオキシメチル−ピペリジン誘導体および関連化合物
US7560471B2 (en) Indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
JP4977760B2 (ja) 鉱質コルチコイド受容体拮抗薬としてのピラゾリン化合物
AU2014267974B2 (en) Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
EA026692B1 (ru) Стимуляторы sgc
EP2491024B1 (en) Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
JPH04235974A (ja) 新規なイミダゾール誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
EP2460787A1 (en) Amide compounds and their use as PGE2 antagonists.
JPH04230369A (ja) イミダゾールの新規な硫黄誘導体、その製造方法、得られる新規な中間体、薬物としてのその使用、及びそれを含有する医薬組成物
JPH061789A (ja) ピリジンの新規な二環式誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
RU2211834C2 (ru) 2-(арилфенил)аминоимидазолиновые производные и фармацевтическая композиция на их основе
JP2010527986A (ja) スピロ環状キナゾリン誘導体およびｐｄｅ７阻害剤としてのその使用
US20080051463A1 (en) Anthracene compounds and their use for treating benign and malignant tumor disorders
JPH09509925A (ja) インドールの新規な四置換誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての用途及びそれらを含有する製薬組成物
JPH01104038A (ja) アラルキルアミノアルコキシフェニル誘導体、その製法およびそれを含有する組成物
JP4707321B2 (ja) アンギオテンシンｉｉアゴニストとして有用な三環式化合物
NL2000336C2 (nl) Spirocyclische derivaten.
JP2003502420A (ja) 新たな薬学的に活性な化合物
JP2007186422A (ja) アリールスルフィド誘導体
JP2003523333A (ja) ベンジルの４−イミダゾール誘導体ならびに限定されたベンジルスルホンアミド、スルファミド、尿素、カルバメート及びアミド、ならびにα１Ａ作用物質としてのそれらの使用
JP7231610B2 (ja) インドール誘導体及びその使用
WO2026068756A1 (en) Novel uracil derivatives as gabab positive allosteric modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090415